Pharmexa Presents New Data from Two Experimental Flu Vaccines on International Vaccine Conference
HØRSHOLM, Denmark, Sept. 6, 2007---Pharmexa's abstract "T-Lymphocyte Epitope Based Vaccine for Pandemic Influenza" has been selected for oral presentation at the international scientific conference "Vaccine Congress" which takes place in Amsterdam from 7-9th December 2007. Pharmexa's hypothesis is that vaccines based on conserved cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) influenza-derived epitopes will induce immune responses with the capability to control influenza virus infections. A potential unique advantage of this type of vaccine is that it may induce immune responses that target the variant influenza viruses that emerge without redesign and reformulation.
Furthermore, Pharmexa's abstract "Influenza H5 Vaccine: In Need of "Help"" has also been selected for presentation. A recombinant protein vaccine based on the H5 influenza virus surface protein could be a highly attractive product due to ease of manufacture and long-term stability. However, similar recombinant protein vaccine candidates have proven to be suboptimal in terms of immunogenicity and require repeated administration with high doses. Pharmexa's hypothesis is that the immunogenicity of a recombinant protein H5 vaccine can be increased through the addition of the potent "Universal" helper epitope, PADRE®.
At the conference, Pharmexa will present data from these two novel influenza vaccine concepts, which combine Pharmexa's long standing expertise within the field of recombinant protein vaccines with its patented Epitope Identification System (EIS®) and poly-epitope DNA vaccine technologies.
Hørsholm, September 7, 2007
Jakob Schmidt Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.
Posted: September 2007
